Mechanisms of Action of Anti-Seizure Medications
Anti-seizure medications work through four primary mechanisms: modulation of voltage-gated ion channels, enhancement of GABAergic inhibition, attenuation of glutamatergic excitation, and modulation of presynaptic neurotransmitter release. 1
1. Voltage-Gated Ion Channel Modulation
Sodium Channel Blockers
- Lamotrigine, phenytoin, and carbamazepine function as voltage-gated sodium channel (VGSC) modulators that stabilize presynaptic neuronal membranes and prevent excessive release of excitatory neurotransmitters, particularly glutamate and aspartate. 2
- These agents work best against focal seizures due to their mechanism of stabilizing neuronal membranes during rapid firing. 3
- Lamotrigine demonstrates a favorable cognitive profile with no statistically significant impairment in arousal, sensory-perceptual, or cognitive functions at doses of 50-300 mg/day, distinguishing it from carbamazepine which shows significant impairment in these domains. 2
Calcium Channel Blockers
- Ethosuximide inhibits T-type calcium channels and works best against absence seizures, a type of generalized seizure. 1, 3
Potassium Channel Openers
- Retigabine (ezogabine) opens voltage-gated potassium channels to reduce neuronal excitability. 1
2. Enhancement of GABA-Mediated Inhibitory Neurotransmission
- Benzodiazepines, tiagabine, and vigabatrin enhance GABA type A receptor-mediated inhibition to suppress seizure activity. 1
- Ganaxolone, one of the most recently FDA-approved ASMs, acts as a GABAAR agonist representing a newer approach to GABAergic modulation. 4
- GABA-ergic drugs typically have greater impact on arousal function and may cause cognitive impairment compared to other mechanisms. 5
3. Attenuation of Glutamate-Mediated Excitatory Neurotransmission
- Perampanel inhibits glutamatergic excitatory neurotransmission to reduce seizure activity. 1
- This mechanism may provide neuroprotective or antiepileptogenic effects beyond simple seizure suppression. 6
4. Modulation of Presynaptic Neurotransmitter Release
SV2A-Mediated Mechanism (Levetiracetam & Brivaracetam)
- Levetiracetam binds to synaptic vesicle protein 2A (SV2A), a glycoprotein that regulates vesicle exocytosis, representing a novel anticonvulsant mechanism distinct from GABA-ergic or sodium-channel agents. 7
- The drug reaches its intravesicular binding site through activity-dependent vesicular endocytosis, entering recycling synaptic vesicles during neuronal firing, which explains the need for a prolonged incubation period before full effect is observed. 7
- This SV2A-mediated mechanism confers broad-spectrum efficacy across partial-onset seizures, myoclonic seizures, and generalized tonic-clonic seizures. 7, 5
- At therapeutic doses of 500-2000 mg/day, levetiracetam has minimal impact on arousal function and does not produce measurable cognitive impairment, reflecting its selective action on hyperactive synapses. 7, 5
- In status epilepticus, a single IV dose of 30 mg/kg results in seizure cessation in approximately 68-73% of patients. 7
Other Presynaptic Modulators
- Gabapentin and pregabalin also modulate neurotransmitter release via presynaptic actions, though pregabalin was found to be less effective than lamotrigine in comparative trials. 1, 8
Clinical Implications by Mechanism
Mechanism Predicts Seizure Type Efficacy
- Sodium channel blockers work best against focal seizures. 3
- Calcium channel blockers are most effective against absence seizures. 3
- SV2A modulators provide broad-spectrum coverage across multiple seizure types. 7, 5
Cognitive and Functional Impact Varies by Mechanism
- VGSC modulators like lamotrigine and SV2A modulators like levetiracetam have minimal cognitive impact, while GABA-ergic drugs and some sodium channel blockers like carbamazepine show greater impairment. 2, 5
- This distinction is critical when selecting therapy for patients requiring preserved cognitive function.
Common Pitfalls
- Avoid combining ASMs with similar mechanisms of action, as this increases risk of pharmacodynamic interactions without improving efficacy. 8
- Recognize that some ASMs have multiple mechanisms, and it may be unclear which mechanism is clinically most important for a given patient. 3
- Be aware that optimal ASM selection requires matching mechanism to seizure type—using sodium channel blockers for absence seizures or calcium channel blockers for focal seizures will be suboptimal. 3